Loading...

Hypera

OTCPK:HYPM.Y
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HYPM.Y
OTCPK
R$18B
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. US
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/06/16 00:18
Company description

Hypera S.A. operates as a pharmaceutical company in Brazil. The last earnings update was 51 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
HYPM.Y Share Price and Events
7 Day Returns
-0.7%
OTCPK:HYPM.Y
-0.5%
US Pharmaceuticals
0.5%
US Market
1 Year Returns
2%
OTCPK:HYPM.Y
6%
US Pharmaceuticals
0.8%
US Market
HYPM.Y Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hypera (HYPM.Y) -0.7% 4.2% -1.4% 2% -10.5% -13.1%
US Pharmaceuticals -0.5% 0.9% -2.7% 6% 9.1% 14%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • HYPM.Y underperformed the Pharmaceuticals industry which returned 6% over the past year.
  • HYPM.Y outperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
HYPM.Y
Industry
5yr Volatility vs Market

HYPM.Y Value

 Is Hypera undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Hypera to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Hypera.

OTCPK:HYPM.Y Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:HYPM.Y
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 34%) (3.15%)) 		0.767
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%) 		7.5%

Discounted Cash Flow Calculation for OTCPK:HYPM.Y using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Hypera is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:HYPM.Y DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (BRL, Millions) Source Present Value
Discounted (@ 7.5%)
2019 970.00 Analyst x1 902.34
2020 908.50 Analyst x4 786.18
2021 1,224.50 Analyst x2 985.73
2022 1,192.00 Analyst x1 892.64
2023 1,179.30 Est @ -1.07% 821.53
2024 1,180.17 Est @ 0.07% 764.79
2025 1,190.44 Est @ 0.87% 717.64
2026 1,207.44 Est @ 1.43% 677.12
2027 1,229.40 Est @ 1.82% 641.34
2028 1,255.13 Est @ 2.09% 609.09
Present value of next 10 years cash flows R$7,798.40
OTCPK:HYPM.Y DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= R$1,255.13 × (1 + 2.73%) ÷ (7.5% – 2.73%) 		R$27,042.59
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= R$27,042.59 ÷ (1 + 7.5%)10 		R$13,123.34
OTCPK:HYPM.Y Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= R$7,798.40 + R$13,123.34 		R$20,921.75
Equity Value per Share
(BRL)		 = Total value / Shares Outstanding
= R$20,921.75 / 632.11 		R$33.1
OTCPK:HYPM.Y Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:HYPM.Y represents 0.25034x of BOVESPA:HYPE3
(This could be a different class, a depositary receipt, a different currency, or all of these things.) 		0.25034x
Value per Share
(Listing Adjusted, USD)		 = Value per Share (BRL) x Listing Adjustment Factor
= R$ 33.10 x 0.25034 		$8.29
Value per share (USD) From above. $8.29
Current discount Discount to share price of $7.26
= -1 x ($7.26 - $8.29) / $8.29 		12.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Hypera is available for.
Intrinsic value
12%
Share price is $7.26 vs Future cash flow value of $8.29
Current Discount Checks
For Hypera to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Hypera's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Hypera's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hypera's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hypera's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:HYPM.Y PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in BRL R$1.84
BOVESPA:HYPE3 Share Price ** BOVESPA (2019-06-14) in BRL R$29
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.22x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hypera.

OTCPK:HYPM.Y PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BOVESPA:HYPE3 Share Price ÷ EPS (both in BRL)

= 29 ÷ 1.84

 15.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hypera is good value based on earnings compared to the US Pharmaceuticals industry average.
  • Hypera is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Hypera's expected growth come at a high price?
Raw Data
OTCPK:HYPM.Y PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts		 7.7%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.55x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

OTCPK:HYPM.Y PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 15.75x ÷ 7.7%

 2.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hypera is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Hypera's assets?
Raw Data
OTCPK:HYPM.Y PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in BRL R$13.33
BOVESPA:HYPE3 Share Price * BOVESPA (2019-06-14) in BRL R$29
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:HYPM.Y PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BOVESPA:HYPE3 Share Price ÷ Book Value per Share (both in BRL)

= 29 ÷ 13.33

 2.18x

* Primary Listing of Hypera.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hypera is good value based on assets compared to the US Pharmaceuticals industry average.
Show me more potentially undervalued companies in the Pharmaceuticals industry
X
Value checks
We assess Hypera's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
    5. Hypera has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HYPM.Y Future Performance

 How is Hypera expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hypera expected to grow at an attractive rate?
  • Hypera's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Hypera's earnings growth is positive but not above the United States of America market average.
  • Hypera's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:HYPM.Y Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:HYPM.Y Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 7.7%
OTCPK:HYPM.Y Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 14.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:HYPM.Y Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in BRL Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:HYPM.Y Future Estimates Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 5,298 2
2021-12-31 4,730 1,365 1,411 8
2020-12-31 4,389 1,132 1,276 10
2019-12-31 3,411 932 1,192 5
OTCPK:HYPM.Y Past Financials Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income *
2019-03-31 3,180 1,005 1,164
2018-12-31 3,724 1,066 1,135
2018-09-30 3,789 1,108 1,288
2018-06-30 3,716 981 1,251
2018-03-31 3,613 943 1,200
2017-12-31 3,500 933 1,111
2017-09-30 3,291 903 819
2017-06-30 3,226 950 795
2017-03-31 3,216 868 743
2016-12-31 3,228 882 647
2016-09-30 3,202 828 557
2016-06-30 3,129 683 432

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Hypera's earnings are expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
  • Hypera's revenue is expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:HYPM.Y Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Hypera Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HYPM.Y Future Estimates Data
Date (Data in BRL Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 2.17 2.46 2.01 4.00
2020-12-31 1.97 2.19 1.80 5.00
2019-12-31 1.83 1.92 1.69 5.00
OTCPK:HYPM.Y Past Financials Data
Date (Data in BRL Millions) EPS *
2019-03-31 1.84
2018-12-31 1.80
2018-09-30 2.03
2018-06-30 1.98
2018-03-31 1.90
2017-12-31 1.76
2017-09-30 1.30
2017-06-30 1.26
2017-03-31 1.18
2016-12-31 1.02
2016-09-30 0.88
2016-06-30 0.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Hypera is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Hypera's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hypera has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HYPM.Y Past Performance

  How has Hypera performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hypera's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hypera has delivered over 20% year on year earnings growth in the past 5 years.
  • Hypera's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Hypera's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.
Earnings and Revenue History
Hypera's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hypera Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HYPM.Y Past Revenue, Cash Flow and Net Income Data
Date (Data in BRL Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 3,180.03 1,164.03 1,469.21
2018-12-31 3,724.31 1,135.40 1,481.23
2018-09-30 3,788.66 1,287.66 1,507.86
2018-06-30 3,715.52 1,250.99 1,476.82
2018-03-31 3,612.85 1,200.18 1,430.26
2017-12-31 3,499.90 1,111.48 1,409.69
2017-09-30 3,290.68 818.63 1,397.40
2017-06-30 3,226.03 794.68 1,379.86
2017-03-31 3,215.70 742.80 1,394.17
2016-12-31 3,228.09 647.17 1,371.66
2016-09-30 3,201.58 557.27 1,360.10
2016-06-30 3,128.92 432.40 1,339.41
2016-03-31 3,046.20 348.73 1,322.83
2015-12-31 2,956.65 345.49 1,307.40
2015-09-30 1,589.31 262.93 773.80
2015-06-30 2,038.57 326.40 943.83
2015-03-31 2,446.97 360.07 1,094.99
2014-12-31 2,768.10 337.89 1,245.13
2014-09-30 4,498.12 399.85 1,913.42
2014-06-30 4,422.82 356.97 1,863.02
2014-03-31 4,359.18 249.13 1,850.60
2013-12-31 4,258.74 258.82 1,803.82
2013-09-30 4,166.62 332.17 1,727.40
2013-06-30 4,047.15 324.15 1,681.45
2013-03-31 3,935.01 278.89 1,626.18
2012-12-31 3,873.68 228.07 1,627.15
2012-09-30 3,688.79 32.91 1,593.03
2012-06-30 3,528.71 -231.75 1,543.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Hypera has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Hypera used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Hypera's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Hypera's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hypera has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HYPM.Y Health

 How is Hypera's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hypera's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hypera is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hypera's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hypera's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hypera Company Filings, last reported 2 months ago.

OTCPK:HYPM.Y Past Debt and Equity Data
Date (Data in BRL Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 8,425.76 576.53 964.64
2018-12-31 8,267.67 586.86 1,646.87
2018-09-30 8,172.46 535.77 1,525.30
2018-06-30 8,062.50 446.49 1,179.27
2018-03-31 7,910.99 509.36 972.19
2017-12-31 7,737.76 676.00 1,522.14
2017-09-30 8,035.47 658.27 1,400.58
2017-06-30 7,849.40 664.00 2,115.30
2017-03-31 8,521.68 889.59 2,171.93
2016-12-31 8,708.47 907.56 1,348.01
2016-09-30 9,033.28 1,362.45 1,156.23
2016-06-30 9,067.73 1,933.04 1,836.06
2016-03-31 9,040.80 2,192.94 2,054.88
2015-12-31 8,030.46 4,963.03 2,756.14
2015-09-30 7,750.15 5,484.13 1,616.82
2015-06-30 7,680.03 5,030.91 1,618.72
2015-03-31 7,567.87 5,115.92 1,667.36
2014-12-31 7,475.96 4,866.78 1,829.91
2014-09-30 7,405.89 4,706.50 1,824.60
2014-06-30 7,286.08 4,458.62 1,719.93
2014-03-31 7,154.36 4,301.30 1,464.67
2013-12-31 7,078.58 4,077.18 1,158.83
2013-09-30 7,017.18 4,964.64 2,171.25
2013-06-30 6,934.28 4,553.57 1,734.84
2013-03-31 6,976.08 4,427.55 1,826.87
2012-12-31 6,868.37 4,437.65 1,736.40
2012-09-30 6,740.04 4,822.31 2,163.55
2012-06-30 6,668.29 5,034.40 2,298.49
  • Hypera's level of debt (6.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (60.1% vs 6.8% today).
  • Debt is well covered by operating cash flow (174.3%, greater than 20% of total debt).
  • Hypera earns more interest than it pays, coverage of interest payments is not a concern.
Show me more healthy companies in the Pharmaceuticals industry
X
Financial health checks
We assess Hypera's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Hypera has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HYPM.Y Dividends

 What is Hypera's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.34%
Current annual income from Hypera dividends. Estimated to be 3.72% next year.
If you bought $2,000 of Hypera shares you are expected to receive $67 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Hypera's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.47%).
  • Hypera's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:HYPM.Y Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:HYPM.Y Future Dividends Estimate Data
Date (Data in R$) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 1.17 8.00
2020-12-31 1.12 10.00
2019-12-31 0.96 9.00
OTCPK:HYPM.Y Past Annualized Dividends Data
Date (Data in R$) Dividend per share (annual) Avg. Yield (%)
2019-02-22 0.970 3.533
2018-02-23 2.221 7.332
2017-05-02 0.901 2.825
2017-02-20 1.112 3.885
2017-02-17 1.112 4.079
2016-10-28 0.500 1.903
2016-07-22 0.500 1.825
2016-02-22 0.039 0.143
2016-02-19 0.039 0.162
2014-11-10 0.000 0.000
2014-10-27 0.000 0.000
2014-07-25 0.000 0.000
2014-04-25 0.000 0.000
2014-02-24 0.000 0.000
2013-03-07 0.163 0.967
2013-03-06 0.000 0.000
2012-11-12 0.000 0.000
2012-11-09 0.000 0.000
2012-08-13 0.000 0.000
2012-08-10 0.000 0.000
2012-05-07 0.000 0.000
2012-03-12 0.000 0.000
2011-08-15 0.121 1.210
2011-05-09 0.121 0.867
2011-03-22 0.121 0.583

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hypera has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Dividend payments have increased, but Hypera only paid a dividend in the past 8 years.
Current Payout to shareholders
What portion of Hypera's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.9x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (2x coverage).
X
Income/ dividend checks
We assess Hypera's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hypera afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Hypera has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HYPM.Y Management

 What is the CEO of Hypera's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Breno Pires de Oliveira
CEO Bio

Mr. Breno Toledo Pires De Oliveira serves as Chief Executive Officer of Hypera S.A. Previously, he served as Chief Financial Officer and Investor Relations Officer at HYPERA S.A. (formerly known as Hypermarcas S.A.). Also served as Treasury Director.

CEO Compensation
  • Insufficient data for Breno to compare compensation growth.
  • Insufficient data for Breno to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Breno Pires de Oliveira

TITLE
Chief Executive Officer

Adalmario Satheler do Couto

TITLE
Investor Relations Officer & CFO

Carlos Roberto Scorsi

TITLE
Chief Operating officer
AGE
57
TENURE
7.8 yrs

Juliana Damião Salem

TITLE
Chief Legal & Compliance Officer

Nelson José de Mello

TITLE
Chief Corporate Relations Officer
AGE
60

Hélio Segouras

TITLE
Head of Consumer Health

Claudio dos Santos

TITLE
President of Pharma & Director
AGE
54

Martim Mattos

TITLE
Secretary
AGE
39

Luiz Eduardo Violland

TITLE
Chief Executive Officer of the Pharmaceutical Division

Nicolas Fischer

TITLE
Chief Executive Officer of the Consumer Division
Board of Directors

Claudio dos Santos

TITLE
President of Pharma & Director
AGE
54
TENURE
12.4 yrs

Esteban Malpica Fomperosa

TITLE
Director
AGE
69

Jairo Loureiro

TITLE
Independent Director

Luciana Fleischner

TITLE
Director
AGE
44

Joao De Queiroz Filho

TITLE
Director
AGE
66

Bernardo Malpica Hernández

TITLE
Director
AGE
53

David Neto

TITLE
Director

Marcelo Goncalves

TITLE
Director

Marcelo Filho

TITLE
Director

Maria Ferreira Lacerda

TITLE
Independent Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Hypera's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Hypera has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HYPM.Y News

Simply Wall St News

HYPM.Y Company Info

Description

Hypera S.A. operates as a pharmaceutical company in Brazil. The company offers prescription medications under the Farmasa, Neo Química, and Luper brands; and over-the-counter medications comprising laxative, antacid, antispasmodic, topical antiseptic, topical, nasal decongestant, and other drugs under Gelol, Anapyon, Biotônico Fontoura, Epocler, Merthiolate, Tamarine, and Rinosoro brands. It also provides similars and generics under the Neo Química brand; dermocosmetics under the Lanidrant, Agecare, Dersab, Epidac, Epidrat, Episol, Hidramamy, Creme rejuvenecedor, Blancy, and Pielus brands; and food supplements and sweeteners. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. The company was founded in 2001 and is headquartered in São Paulo, Brazil.

Details
Name: Hypera S.A.
HYPM.Y
Exchange: OTCPK
Founded: 2001
R$4,721,514,761
632,113,140
Website: http://www.hyperapharma.com.br
Address: Hypera S.A.
Av. Magalhães de Castro, 4800,
24° andar,
São Paulo,
São Paulo, 05676-120,
Brazil
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BOVESPA HYPE3 Registered Common Shares Bolsa de Valores de Sao Paulo BR BRL 18. Apr 2008
OTCPK HYPM.Y SPONSORED ADR Pink Sheets LLC US USD 29. Apr 2010
BST HM6A SPONSORED ADR Boerse-Stuttgart DE EUR 29. Apr 2010
Number of employees
Current staff
Staff numbers
7,089
Hypera employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 00:18
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/12
Last earnings filing: 2019/04/26
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)